Pazopanib for the treatment of renal cell carcinoma

被引：16
|
作者：
Welsh, Sarah J. [1 ]
Fife, Kate [1 ]
机构：
[1] Cambridge Univ Hosp NHS Fdn Trust, Cambridge CB2 0QQ, England
来源：
FUTURE ONCOLOGY | 2015年 / 11卷 / 08期
关键词：
antiangiogenic; kidney; pazopanib; renal cancer; treatment; tyrosine kinase inhibitor; DOUBLE-BLIND; PHASE-III; TARGETED THERAPIES; SUNITINIB; SAFETY; EFFICACY; TRIAL;
D O I：
10.2217/fon.14.274
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The incidence and mortality from renal cell cancer (RCC) is increasing. RCC tumors are particularly vascular in nature as a result of disruption of the VHL gene and/or its upstream pathway leading to upregulation of the hypoxia-inducible factor transcription factor. The hypoxia-inducible factor pathway drives angiogenesis by upregulating VEGF and bFGF, amongst other proangiogenic downstream target genes. Therapies which target angiogenesis have been successful in treating metastatic RCC (mRCC) and the receptor tyrosine kinase inhibitor, pazopanib, is licensed for first line treatment of mRCC. This review details the past, current and future roles of pazopanib in the treatment of mRCC.
引用
收藏
页码：1169 / 1179
页数：11
相关论文
共 50 条
  • [21] Effectiveness of pazopanib and SBRT in metastatic renal cell carcinoma
    Cihan, Yasemin Benderli
    WORLD JOURNAL OF UROLOGY, 2018, 36 (11) : 1797 - 1798
  • [22] Benefits of pazopanib over sunitinib for renal cell carcinoma
    Granovetter, Michael
    LANCET ONCOLOGY, 2016, 17 (03): : E93 - E93
  • [23] Effectiveness of pazopanib and SBRT in metastatic renal cell carcinoma
    Yasemin Benderli Cihan
    World Journal of Urology, 2018, 36 : 1797 - 1798
  • [24] Pazopanib for the treatment of advanced renal cell cancer
    Escudier, Bernard
    Albiges, Laurence
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (06): : 605 - 616
  • [25] Pazopanib or sunitinib for metastatic renal-cell carcinoma?
    Bennet, Neil
    LANCET ONCOLOGY, 2013, 14 (11): : E442 - E442
  • [26] Pazopanib The Newest Tyrosine Kinase Inhibitor for the Treatment of Advanced or Metastatic Renal Cell Carcinoma
    Keisner, Sidney V.
    Shah, Sachin R.
    DRUGS, 2011, 71 (04) : 443 - 454
  • [27] COST-EFFECTIVENESS OF PAZOPANIB COMPARED TO SUNITINIB IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA
    Fouad, A.
    Atia, A.
    Omar, Y.
    Shawky, M.
    Sakr, M.
    VALUE IN HEALTH, 2016, 19 (07) : A733 - A734
  • [28] Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma
    Santoni, Matteo
    Conti, Alessandro
    Porta, Camillo
    Procopio, Giuseppe
    Sternberg, Cora N.
    Basso, Umberto
    De Giorgi, Ugo
    Bracarda, Sergio
    Rizzo, Mimma
    Ortega, Cinzia
    Massari, Francesco
    Iacovelli, Roberto
    Derosa, Lisa
    Masini, Cristina
    Milella, Michele
    Di Lorenzo, Giuseppe
    Atzori, Francesco
    Pagano, Maria
    Buti, Sebastiano
    De Vivo, Rocco
    Mosca, Alessandra
    Rossi, Marta
    Paglino, Chiara
    Verzoni, Elena
    Cerbone, Linda
    Muzzonigro, Giovanni
    Falconi, Massimo
    Montironi, Rodolfo
    Burattini, Luciano
    Santini, Daniele
    Cascinu, Stefano
    JOURNAL OF UROLOGY, 2015, 193 (01): : 41 - 47
  • [29] Pazopanib in the treatment of advanced renal cell carcinoma (vol 8, pg 61, 2016)
    Cella, David
    Beaumont, Jennifer L.
    THERAPEUTIC ADVANCES IN UROLOGY, 2016, 8 (04) : 291 - 291
  • [30] Starting with low dose pazopanib in the treatment of Japanese patients with metastatic renal cell carcinoma
    Akatsuka, J.
    Kimura, G.
    Shibayama, K.
    Sano, M.
    Endo, Y.
    Takeda, H.
    Hamasaki, T.
    Kondo, Y.
    ANNALS OF ONCOLOGY, 2017, 28
12345